Gufic BioSciences Ltd

Gufic BioScience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Gufic BioSciences Ltd

₹ 364 2.03%
05 Jun 9:47 a.m.
gufic.com BSE: 509079 NSE: GUFICBIO
About

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

Key Points

Business Segments
1) Domestic Branded Business: The company develops pharmaceutical formulations in various forms, including injectables, syrups, ointments, lotions, and herbal products. It serves 15+ therapeutic areas, including critical care, infertility, nutraceuticals, etc with a portfolio of 100+ products, 200+ SKUs, and a network of 30,000+ prescribers. It is one of the largest manufacturers of Lyophilized Injections in India. The company aims to expand into Biologicals and Immuno-Oncology. [1] [2]

Website BSE NSE
  • Market Cap ₹ 3,648 Cr.
  • Current Price ₹ 364
  • High / Low ₹ 409 / 268
  • Stock P/E 56.8
  • Book Value ₹ 66.3
  • Dividend Yield 0.03 %
  • ROCE 12.3 %
  • ROE 10.1 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 5.34 times its book value
  • Company has a low return on equity of 12.8% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
215 202 195 203 204 208 205 224 237 231 252
176 165 161 167 166 174 179 190 199 198 205
Operating Profit 39 36 34 36 39 34 26 33 38 33 47
OPM % 18% 18% 18% 18% 19% 16% 13% 15% 16% 14% 19%
0 0 1 1 0 2 0 1 2 1 -1
Interest 4 3 4 5 5 5 8 9 10 8 9
Depreciation 4 4 4 4 4 5 8 8 8 8 8
Profit before tax 31 30 27 28 29 26 11 17 23 18 29
Tax % 25% 25% 26% 26% 26% 26% 27% 24% 26% 30% 24%
23 22 20 21 22 19 8 13 17 12 22
EPS in Rs 2.39 2.22 2.00 2.08 2.17 1.93 0.77 1.30 1.68 1.24 2.18
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
807 820 944
657 684 793
Operating Profit 150 136 151
OPM % 19% 17% 16%
-0 4 3
Interest 17 25 37
Depreciation 17 21 31
Profit before tax 116 94 87
Tax % 26% 26% 26%
86 70 64
EPS in Rs 8.59 6.95 6.40
Dividend Payout % 1% 1% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -8%
Stock Price CAGR
10 Years: 24%
5 Years: 13%
3 Years: 22%
1 Year: -4%
Return on Equity
10 Years: %
5 Years: %
3 Years: 13%
Last Year: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Equity Capital 10 10 10
Reserves 523 591 655
333 336 405
227 232 273
Total Liabilities 1,093 1,169 1,342
159 506 491
CWIP 307 22 22
Investments 2 2 2
625 640 827
Total Assets 1,093 1,169 1,342

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
-7 123 45
-102 -71 -31
82 -37 32
Net Cash Flow -27 15 46
Free Cash Flow -116 52 14
CFO/OP 13% 107% 38%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Mar 2026
Debtor Days 149 140 115
Inventory Days 188 211 281
Days Payable 156 155 172
Cash Conversion Cycle 181 197 224
Working Capital Days 97 93 80
ROCE % 13% 12%

Insights

In beta
Mar 2015 Jun 2021 Mar 2023 Mar 2024 Sep 2025
Products Registered Globally
Count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Total Employees/Workers
Count ・Standalone data
Total Field Force
Count ・Standalone data
Lyophilized Vials Installed Capacity (Navsari Unit I + II)
mn vials p.a. ・Standalone data
Research & Development Spend
Rs. Lakhs ・Standalone data
Installed Capacity - Indore Unit III (Liquid Ampoules)
mn units p.a. ・Standalone data
Installed Capacity - Indore Unit III (Lyophilized Injections)
mn vials p.a. ・Standalone data
Retail Reach
Count ・Standalone data
Doctor Reach
Count ・Standalone data
Patents Granted
Count ・Standalone data
Total SKUs
Count ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
75.00% 75.00% 72.51% 72.51% 72.51% 72.51% 72.51% 72.51% 72.51% 72.50% 72.50% 72.50%
0.70% 0.72% 0.47% 0.12% 0.23% 0.23% 0.30% 0.31% 0.32% 0.33% 0.44% 0.42%
1.16% 1.63% 1.72% 2.20% 2.38% 2.51% 2.99% 3.39% 3.38% 3.66% 3.74% 3.83%
23.12% 22.64% 25.29% 25.17% 24.89% 24.75% 24.20% 23.79% 23.81% 23.51% 23.30% 23.23%
No. of Shareholders 38,62436,55734,42434,69532,25032,82533,29931,84431,87631,42030,36229,223

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls